Logo1
ICCS - 2025 ICCS Practical Clinical Cytometry Course (PACE ONLY)
Mr pencil

How would you like your name to appear on your certificate?



What activities did you attend at the event?
Agreement
By completing this form, you attest that you have participated in all selected activities in thier entirety.
Please rate the following:
The program was relevant to my work.
Content matched stated objectives.
Quality of facilities/facility accomodations or website/accessibility if online.
How well did the educational sessions give a balanced view of therapeutic options, including the use of generic names?
Usefulness of handouts/AV/technology.
If you rated any of the above questions with 'fair,' 'poor,' 'disagree,' or 'strongly disagree' please explain in detail (e.g. session title, speaker name, situtation):
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) of this session as a group. You will have the opportunity to elaborate on an individual speaker in the following question. 
Objective 1: Demonstrate increased knowledge concerning the use of flow cytometry and its application to patient diagnosis and care
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
The teaching methods used were appropriate to the objectives
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. content issues, teaching ability, credentials or expertise, etc. - please use the space below:
Objective 2: Describe the latest techniques and approved standards in flow cytometry
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
The teaching methods used were appropriate to the objectives
Objective 3: Demonstrate increased understanding of the utility of flow cytometry in the diagnosis of leukemia and lymphoma and related diagnostic guidelines
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
The teaching methods used were appropriate to the objectives
Describe the utility of flow cytometry in the diagnosis of benign and malignant hematolymphoid disorders
Recognize the components of a flow cytometer
Discuss the principles of daily, weekly, and monthly instrument Quality Control.
Discuss the steps and perform instrument optimization and compensation using software emulators that resemble actual flow cytometers
Demonstrate and run controls as a way to monitor the compensation settings
Discuss the principles of daily, weekly, and monthly instrument Quality Control.
Discuss the steps and perform instrument optimization and compensation using software emulators that resemble actual flow cytometers
Demonstrate and run controls as a way to monitor the compensation settings
Use analytic software to gate, identify, and analyze hematolymphoid populations using provided data sets
Recognize normal myeloid and lymphoid populations and their maturation patterns by flow cytometry
Describe the potential benefits and drawbacks of templates in analysis of flow cytometric data.
Use analytic software to gate, identify, and analyze hematolymphoid populations using provided data sets
Recognize normal myeloid and lymphoid populations and their maturation patterns by flow cytometry
Describe the potential benefits and drawbacks of templates in analysis of flow cytometric data.
Describe the steps required to introduce a new or modied assay to the lab test menu.
Describe the steps required to validate a new instrument platform to an existing lab or a brand new lab.
Provide guidelines for meeting regulatory requirements for a new or modified panel or instrument
Describe tools and techniques that can be used in preparation for an inspection by a regulatory agency.
Review the inspection process typically used to assess a laboratory's compliance with all inspection checklist items.
Review the list of most common deficiencies as a way to be proactive in preventing these deficiencies
Describe an approach to panel design for a flow cytometry assay and what elements should be considered
Critically evaluate a flow cytometry panel for spectral crosstalk issues and population resolution
Assess antigen density and fluorochrome intensity and apply to panel design
Describe an approach to panel design for a flow cytometry assay and what elements should be considered
Critically evaluate a flow cytometry panel for spectral crosstalk issues and population resolution
Assess antigen density and fluorochrome intensity and apply to panel design
Distinguish clonal and aberrant mature B- and T-cell phenotypes from their normal counterparts
Describe pitfalls associated with the use of kappa and lambda to identify B-cell malignancies
Associate particular B- and T-cell phenotypes with specific malignancies
Distinguish clonal and aberrant mature B- and T-cell phenotypes from their normal counterparts
Describe pitfalls associated with the use of kappa and lambda to identify B-cell malignancies
Associate particular B- and T-cell phenotypes with specific malignancies
Describe preanalytic, analytic, and postanalytic troubleshooting issues in flow cytometry testing along with ways to prevent problems before they arise
Using case studies, identify diagnostic pitfalls in flow cytometry data analysis and strategies for troubleshooting artifacts and potential errors in flow cytometry data
Identify plasma cells by their common immunophenotypic characteristics
Distinguish normal plasma cells from those seen in plasma cell neoplasms
Understand how flow cytometry can be used to assess for measurable residual disease
Use flow cytometry data to diagnose and classify cases of acute lymphoblastic leukemia and acute myeloid leukemia
Describe patterns of antigen expression that differentiate acute leukemias from normal maturation.
Associate particular blast phenotypes with common genetic subtypes of acute leukemia
Use flow cytometry data to diagnose and classify cases of acute lymphoblastic leukemia and acute myeloid leukemia
Describe patterns of antigen expression that differentiate acute leukemias from normal maturation.
Associate particular blast phenotypes with common genetic subtypes of acute leukemia
To become familiar with newer approaches to data analysis in high-dimensional flow cytometry, including dimensionality reduction and cluster analysis.
To understand how some of these approaches may be applied in the clinical setting.
Discuss the principles of daily, weekly, and monthly instrument Quality Control.
Discuss the steps and perform instrument optimization and compensation using software emulators that resemble actual flow cytometers
Demonstrate and run controls as a way to monitor the compensation settings
Use analytic software to gate, identify, and analyze hematolymphoid populations using provided data sets
Recognize normal myeloid and lymphoid populations and their maturation patterns by flow cytometry
Describe the potential benefits and drawbacks of templates in analysis of flow cytometric data.
Use analytic software to gate, identify, and analyze hematolymphoid populations using provided data sets
Recognize normal myeloid and lymphoid populations and their maturation patterns by flow cytometry
Describe the potential benefits and drawbacks of templates in analysis of flow cytometric data.
Use analytic software to gate, identify, and analyze hematolymphoid populations using provided data sets
Recognize normal myeloid and lymphoid populations and their maturation patterns by flow cytometry
Describe the potential benefits and drawbacks of templates in analysis of flow cytometric data.
Describe an approach to panel design for a flow cytometry assay and what elements should be considered
Critically evaluate a flow cytometry panel for spectral crosstalk issues and population resolution
Assess antigen density and fluorochrome intensity and apply to panel design
Describe an approach to panel design for a flow cytometry assay and what elements should be considered
Critically evaluate a flow cytometry panel for spectral crosstalk issues and population resolution
Assess antigen density and fluorochrome intensity and apply to panel design
Distinguish clonal and aberrant mature B- and T-cell phenotypes from their normal counterparts
Describe pitfalls associated with the use of kappa and lambda to identify B-cell malignancies
Associate particular B- and T-cell phenotypes with specific malignancies
Distinguish clonal and aberrant mature B- and T-cell phenotypes from their normal counterparts
Describe pitfalls associated with the use of kappa and lambda to identify B-cell malignancies
Associate particular B- and T-cell phenotypes with specific malignancies
Did this program improve your Skill or Strategy in your role or contribution as a member of the healthcare team?
Please explain how, or why not?
Please answer the following:
Was the educational content scientifically sound?
If faculty spoke about off-label or investigational uses of a product, was that information disclosed to you?
Was the mode of education effective to learning?
If you answered "No" to any of the above questions, please explain.
Did you perceive any commercial bias or influence in the educational content?
If you answered "Yes" to the above question, please detail the situation below (e.g. session title, speaker name):
Were you solicited by sales personnel in an educational area (other areas do not matter) while you attended this educational activity?
If you answered "Yes" to the above question, please explain in detail (e.g. who, when, where):
Do you believe your participation in this activity will positively impact your healthcare team?
Why or why not?
What questions are you having in your practice that you would like to see addressed in an educational activity?

What barriers might you have that would interfere with implementation of new information learned from this training?

How can this training (the overall meeting) be improved to better impact knowledge, strategies/skills, performance and/or patient outcomes?

Additional comments:

Mr question
Provided by amedco